| Abstrakt: |
Objective: To systematically evaluate the long-term efficacy of Bushen Huoxue Decoction combined with vertebroplasty (PVP or PKP) in the treatment of osteoporotic vertebral compression fractures (OVCF), in order to provide evidence-based reference for clinical application. Methods: To ensure the novelty of research data, a computer search was conducted between 2017 and February 2023 to publicly publish all randomized controlled studies and clinical trials at home and abroad on the treatment of OVCF with Bushen Huoxue Decoction combined with vertebroplasty published in CNKI, Wanfang, Vip, PubMed, CBM, and Cochrane libraries. Two researchers independently conducted literature screening and data extraction, evaluated the quality of randomized controlled trials included one by one according to the Cochrane collaboration network standards, and conducted a meta statistical analysis using RevMan5.3 for studies that met the inclusion criteria. Results: A total of 684 patients were included in 7 randomized controlled trials, including 342 patients in the observation group and 342 patients in the control group, with a ratio of 1:1; The meta-analysis results showed that in the observation group, the overall effective rate [RR=1.30, 95% CI (1.14, 1.47), P<0.001], visual analog pain (VAS) score [SMD=1.19, 95% CI (0.77, 1.61), P<0.0001], bone mineral density score [SMD=1.09, 95% CI (0.15, 2.04), P=0.02], COQOL score [SMD =0.99,95%CI(0.68,1.30), P<0.00001], OPG score [SMD=0.48, 95% CI (0.18, 0.77), P=0.002] The RANKL score [SMD=1.33, 95% CI (1.00, 1.65), P<0.0001] was significantly superior to the control group, with statistically significant differences. There was no significant difference in the Oswestry Disability Index (ODI) score [SMD=0.27, 95% CI (-0.03, 0.57), P=0.08], Cobb score [SMD=1.52, 95% CI (-1.05, 4.09), P=0.25], and vertebral height score [SMD=0.43, 95% CI (-0.14, 1.01), P=0.14]. Conclusion: The results show that Bushen Huoxue Decoction combined with vertebroplasty has significant advantages in improving bone mineral density and alleviating pain in patients after OVCF, which is significantly superior to using OVCF alone. [ABSTRACT FROM AUTHOR] |
